Pogastin

Therapeutic Class:
Dosage Forms:
  •   Hydroxyprogesterone Caproate Injection USP 2 ml

How it works ?

Hydroxyprogesterone caproate injection is a progestin indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. The effectiveness of hydroxyprogesterone caproate injection is based on improvement in the proportion of women who delivered < 37 weeks of gestation. There are no controlled trials demonstrating a direct clinical benefit, such as improvement in neonatal mortality and morbidity. Limitation of use: While there are many risk factors for preterm birth, safety and efficacy of hydroxyprogesterone caproate injection has been demonstrated only in women with a prior spontaneous singleton preterm birth. It is not intended for use in women with multiple gestations or other risk factors for preterm birth.
Administer intramuscularly at a dose of 250 mg (1 ml) once weekly (every 7 days) by a healthcare provider Begin treatment between 16 weeks, 0 days and 20 weeks, 6 days of gestation Continue administration once weekly until week 37 (through 36 weeks, 6 days) of gestation or delivery, whichever occurs first
The most common adverse reactions reported in ≥ 2% of subjects and at a higher rate in the Pogastin group than in the control group were injection site reactions (pain [35%], swelling [17%], pruritus [6%], nodule [5%]), urticaria (12%), pruritus (8%), nausea (6%) and diarrhea (2%). Postmarketing Experience The following adverse reactions have been identified during postapproval use of Pogastin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Body as a whole: Local injection site reactions (including erythema, urticaria, rash, irritation, hypersensitivity, warmth); fatigue; fever; hot flashes/flushes Digestive disorders: Vomiting Infections: Urinary tract infection Nervous system disorders: Headache, dizziness Pregnancy, puerperium and perinatal conditions: Cervical incompetence, premature rupture of membranes Reproductive system and breast disorders: Cervical dilation, shortened cervix Respiratory disorders: Dyspnea, chest discomfort
Thromboembolic Disorders Discontinue Pogastin if an arterial or deep venous thrombotic or thromboembolic event occurs. Allergic Reactions Allergic reactions, including urticaria, pruritus and angioedema, have been reported with use of Pogastin. Consider discontinuing the drug if such reactions occur. Decrease in Glucose Tolerance A decrease in glucose tolerance has been observed in some patients on progestin treatment. The mechanism of this decrease is not known. Carefully monitor prediabetic and diabetic women while they are receiving Pogastin. Fluid Retention Because progestational drugs may cause some degree of fluid retention, carefully monitor women with conditions that might be influenced by this effect (e.g., preeclampsia, epilepsy, migraine, asthma, cardiac or renal dysfunction). Depression Monitor women who have a history of clinical depression and discontinue Pogastin if clinical depression recurs. Jaundice Carefully monitor women who develop jaundice while receiving Pogastin and consider whether the benefit of use warrants continuation. Hypertension Carefully monitor women who develop hypertension while receiving Pogastin and consider whether the benefit of use warrants continuation.
Store below 30°C. Protect from light. Do not freeze. Once opened, use immediately and discard any unused contents. Do not use solution if any foreign particles observed. Keep the medicine out of reach and sight of children. For human use only.
2 ml amber color ampoule along with package insert. 500 mg/ 2 ml

F. A. Q

Frequently Asked Questions

Questions are useful tools, they open lines of communication; give us information; improve interactions, facilitate analysis, and many more.

We have below MOQ for:

  1. Tablet, Capsules & Softgel: 200000 Units
  2. Ampoules : 100000 Units
  3. Vials: 10000 Units
  4. Ointment and Cream: 15000 Units
  5. Suppository: 50000 Units
  6. Syrup and Liquid: 10000 Units
  7. Sachets : 50000 Units

We do ready the product within 45-60 days after product artwork confirmation from your side. So, including transit time you can get the product within 90 days maximum, either by Air or Sea route.

A product's “shelf life” generally means the length of time you can expect a product to look and act as expected and to stay safe for use. This length of time varies, depending on the type of product, how it is used, and how it is stored.

Our products come with a minimum of 24 months to a maximum of 36 months of shelf life.

For, Primary packaging we use aluminium foil with 20 to 50 micron size and PVC foil with 350 to 400 micron depending on product characteristics and stability.

For, Secondary packing we do use 300 to 400 GSM FFB Card board.

For, Tertiary packing we do us 7 ply 150 GSM corrugated boxes to prevent the damage during transits.

Yes, we do have available for all dossier documents according to GMP guidelines for the respective country. We do also provide COPP and Free sale certificates (FSC) on demand to customers for special import permit type of commercial orders.

interested? let’s talk.

Contact us directly to receive full information on the product, the formulation, the science behind it, stability data, and more. Our Business Development Manager is a click away.